Trials / Completed
CompletedNCT05544292
Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors
Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors - a Prospective Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 69 (actual)
- Sponsor
- Diakonhjemmet Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RIMRA is a prospective, longitudinal, observational study including patients with de novo symptoms of rheumatic disease or a flare of established rheumatic disease after treatment with an immune check point inhibitor. The aim of the study is to describe the clinical presentation, disease course and outcome of rheumatic irAEs in patients treated with immune check point inhibitors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Antiinflammatory/DMARDs | Antiinflammatory/DMARDs |
Timeline
- Start date
- 2018-03-05
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2022-09-16
- Last updated
- 2025-08-24
Locations
5 sites across 1 country: Norway
Source: ClinicalTrials.gov record NCT05544292. Inclusion in this directory is not an endorsement.